About half of physicians cannot specifically identify a PSP that has been more innovative than others since the beginning of the pandemic. Among those that do, AstraZeneca is more commonly mentioned.
AstraZeneca and Lilly are particularly likely to be mentioned as having PSPs that have been helpful in supporting with paperwork and reducing administrative burden during the pandemic.
Biosimilar drug PSPs are seen as generally quite similar as PSPs for originator drugs. In the few cases where they are seen as inferior, it is mainly because of they do not have as many employees and offer a smaller range of services. We have created a downloadable and shareable infographic based on this research.